# Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

> **NCT02533427** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 15 (actual)

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** SOF/VEL/VOX
- **DRUG:** VOX
- **DRUG:** Norgestimate/ethinyl estradiol

## Key facts

- **NCT ID:** NCT02533427
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-29
- **Primary completion:** 2016-03-18
- **Final completion:** 2016-03-18
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02533427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02533427, "Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02533427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*